Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
前收盘价
US$40.10
+US$0.05 · +0.12%
盘中时间采用ET。市场数据可能有所延迟。
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
日内区间
当前US$40.10
52周区间
当前US$40.10
盘中时间采用ET。市场数据可能有所延迟。
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
日内区间
当前US$40.10
52周区间
当前US$40.10
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.76亿 USD | 2.37亿 USD | 1.98亿 USD | 1.64亿 USD | 1.56亿 USD |
| 销货成本 | 7066万 USD | 6511.7万 USD | 6194万 USD | 5457.7万 USD | 5015.9万 USD |
| 毛利 | 2.06亿 USD | 1.72亿 USD | 1.36亿 USD | 1.1亿 USD | 1.06亿 USD |
| 研究与开发 | 2756.3万 USD | 2479.7万 USD | 2104.2万 USD | 1994.3万 USD | 1628.7万 USD |
| 销售、一般及管理费用 | 1.67亿 USD | 1.43亿 USD | 1.21亿 USD | 1.07亿 USD | 9759.2万 USD |
| 营业费用 | 1.95亿 USD | 1.68亿 USD | 1.42亿 USD | 1.27亿 USD | 1.14亿 USD |
| 利息收入 | 700.7万 USD | 641万 USD | 463.2万 USD | 134.1万 USD | 22.4万 USD |
| 利息支出 | 155.6万 USD | 61.4万 USD | 60万 USD | 36.6万 USD | 4000 USD |
| 折旧和摊销 | 1136.1万 USD | 550.4万 USD | 463.2万 USD | 398.1万 USD | 296.5万 USD |
| 营业利润 | 1104.4万 USD | 451.9万 USD | −646.4万 USD | −1705.8万 USD | −785.4万 USD |
| 净利润 | 1651.8万 USD | 1036.2万 USD | −318.2万 USD | −1670.9万 USD | −747.1万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$61.33
上涨空间 52.94%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.22亿0.12%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI6473.24万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM5408.58万0.07%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4479.1万0.45%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF2370.91万0.02%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO1909.75万0.14%139.17亿 USD0.24%US$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1886.23万0.12%158.4亿 USD0.03%US$53.45+0.17%
iShares Biotechnology ETFIBB1570.48万0.15%108.2亿 USD0.44%US$206.49+3.00%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
iShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。